Pembrolizumab
Showing 1 - 25 of 2,041
Cervical Cancer, HPV-Related Carcinoma, HPV-Related Malignancy Trial run by the Precigen, Inc (PRGN-2009 plus Pembrolizumab,
Not yet recruiting
- Cervical Cancer
- +2 more
- PRGN-2009 plus Pembrolizumab
- Pembrolizumab alone
-
Bethesda, MarylandNational Institute of Health
Nov 27, 2023
Cancer Trial in Villejuif (Pembrolizumab, Pembrolizumab and Olaparib, Pembrolizumab adjuvant)
Not yet recruiting
- Cancer
- Pembrolizumab
- +2 more
-
Villejuif, Val De Marne, FranceGustave Roussy
Oct 30, 2023
NSCLC, Renal Cell Carcinoma, Melanoma Trial (Pembrolizumab co-formulated with hyaluronidase, Pembrolizumab)
Not yet recruiting
- Non-Small Cell Lung Cancer
- +2 more
- Pembrolizumab co-formulated with hyaluronidase
- Pembrolizumab
- (no location specified)
Oct 19, 2023
MSI-H Colorectal Cancer Trial in Pittsburgh (Regorafenib, Pembrolizumab)
Not yet recruiting
- MSI-H Colorectal Cancer
- Regorafenib
- Pembrolizumab
-
Pittsburgh, PennsylvaniaUPMC Hillman Cancer Center
Aug 17, 2023
NSCLC Trial (V940, Pembrolizumab, Placebo)
Not yet recruiting
- Non-small Cell Lung Cancer
- V940
- +2 more
- (no location specified)
Oct 5, 2023
Solid Tumor, Cutaneous Squamous Cell Carcinoma, Endometrial Cancer Trial (favezelimab/pembrolizumab, pembrolizumab, lenvatinib)
Not yet recruiting
- Solid Tumor
- +2 more
- favezelimab/pembrolizumab
- +2 more
- (no location specified)
Sep 7, 2023
Head and Neck Squamous Cell Carcinoma Trial (Zanzalintinib, Zanzalintinib-matched Placebo, Pembrolizumab)
Not yet recruiting
- Head and Neck Squamous Cell Carcinoma
- Zanzalintinib
- +2 more
- (no location specified)
Oct 9, 2023
Triple Negative Breast Tumors Trial (Pembrolizumab injection, Capecitabine tablets, Local radiotherapy)
Not yet recruiting
- Triple Negative Breast Neoplasms
- Pembrolizumab injection
- +2 more
- (no location specified)
Jul 25, 2023
Advanced Solid Tumors Trial (AMG 355, Pembrolizumab)
Not yet recruiting
- Advanced Solid Tumors
- AMG 355
- Pembrolizumab
- (no location specified)
Nov 9, 2023
Lung Cancer Trial (TILT-123, Pembrolizumab)
Not yet recruiting
- Lung Cancer
- TILT-123
- Pembrolizumab
- (no location specified)
Nov 5, 2023
Hodgkin Lymphoma Trial in Cologne (Pembrolizumab)
Not yet recruiting
- Hodgkin Lymphoma
- Pembrolizumab
-
Cologne, Germany1st Department of Medicine, Cologne University Hospital
Sep 19, 2023
Lung Cancer Trial (Sacituzumab Govitecan, Pembrolizumab)
Not yet recruiting
- Lung Cancer
- Sacituzumab Govitecan
- Pembrolizumab
- (no location specified)
Sep 20, 2023
Melanoma Trial (V940, Pembrolizumab, Placebo)
Not yet recruiting
- Melanoma
- V940
- +2 more
- (no location specified)
Jul 12, 2023
Metastatic Urothelial Carcinoma, Urothelial Tumors Trial (Coformulated favezelimab/pembrolizumab, Coformulated
Not yet recruiting
- Metastatic Urothelial Carcinoma
- Urothelial Neoplasms
- Coformulated favezelimab/pembrolizumab
- +3 more
- (no location specified)
Apr 26, 2023
Sinonasal Undifferentiated Carcinoma Trial in Pavia (Pembrolizumab)
Not yet recruiting
- Sinonasal Undifferentiated Carcinoma
- Pembrolizumab
-
Pavia, Lombardia, ItalyIstituti Clinici Scientifici Maugeri
Jun 21, 2023
Head and Neck Squamous Cell Carcinoma, Neoadjuvant Therapy, Pembrolizumab Trial in Beijing (Pembrolizumab, Cisplatin,
Recruiting
- Head and Neck Squamous Cell Carcinoma
- +2 more
- Pembrolizumab
- +7 more
-
Beijing, Beijing, ChinaBeijing Tongren Hospital
Oct 26, 2023
GastroEsophageal Cancer, Gastric Cancer Trial in Tampa (Neratinib, Trastuzumab, Oxaliplatin)
Recruiting
- GastroEsophageal Cancer
- Gastric Cancer
- Neratinib
- +4 more
-
Tampa, FloridaMoffitt Cancer Center
Oct 25, 2023
Pancreatic Cancer Trial in Baltimore (Gemcitabine, Cisplatin, Pembrolizumab)
Not yet recruiting
- Pancreatic Cancer
- Gemcitabine
- +2 more
-
Baltimore, MarylandSKCCC Johns Hopkins
Aug 16, 2023
Metastatic Melanoma, Head and Neck Squamous Cell Carcinoma Trial in Portland (GB1211, Pembrolizumab, Placebo)
Not yet recruiting
- Metastatic Melanoma
- Head and Neck Squamous Cell Carcinoma
- GB1211
- +2 more
-
Portland, OregonProvidence Portland Medical Center
Jun 19, 2023
Recurrent Head Neck Cancer, Recurrent Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Carcinoma Trial in Saint
Not yet recruiting
- Recurrent Head and Neck Cancer
- +5 more
- Ramucirumab
- Pembrolizumab
-
Saint Louis, MissouriWashington University School of Medicine
Jul 30, 2023
Metastatic Melanoma, Unresectable Melanoma, Melanoma Trial (Lifileucel plus Pembrolizumab, Pembrolizumab with Optional Crossover
Not yet recruiting
- Metastatic Melanoma
- +2 more
- Lifileucel plus Pembrolizumab
- Pembrolizumab with Optional Crossover Period
- (no location specified)
Feb 13, 2023